Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment.
Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. It was founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain.The goal of Akelos is to address some of today’s most pressing areas of unmet needs. The company was founded in 2018 and is based in New York, NY, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 22, 2020 | Grant | $1.75M | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |